8-K: Protalix BioTherapeutics Appoints Gilad Mamlok as New CFO, Succeeding Eyal Rubin

Protalix BioTherapeutics, Inc. announced the appointment of Gilad Mamlok as its new Senior Vice President and Chief Financial Officer, effective August 24, 2025, following the resignation of Eyal Rubin.

Summary

• Protalix BioTherapeutics, Inc. appointed Gilad Mamlok as its new Senior Vice President and Chief Financial Officer, with his official role commencing on August 24, 2025.
• Mr. Mamlok succeeds Eyal Rubin, who had previously announced his resignation on April 21, 2025, to pursue other opportunities.
• To ensure a smooth transition, Mr. Mamlok joined the company and is working alongside Mr. Rubin, who will remain available to the company as needed until October 2025.
• Mr. Mamlok, 57, brings three decades of experience in healthcare and technology companies, with an extensive background in capital markets transactions, mergers and acquisitions, business development, investor relations, and corporate governance.
• His compensation package includes a monthly base salary of 81,000 New Israeli Shekels (approximately $24,066) and eligibility for an annual discretionary bonus ranging from four to six monthly salaries, based on achievement of 80% to 120% of agreed-upon annual objectives.
• Mr. Mamlok was granted options to purchase 597,990 shares of the company's common stock at an exercise price of $1.45, which will vest over a three-year period in 12 equal quarterly increments.
• The employment agreement, dated June 13, 2025, also includes a one-time bonus equal to twelve months' salary upon certain change of control transactions and standard executive benefits.

Sentiment

Score: 7

Explanation: The announcement of a new CFO with strong experience in capital markets and M&A, coupled with a planned smooth transition, is generally positive for corporate stability and future strategic execution. The outgoing CFO's departure was previously announced, making this an expected and well-managed transition rather than a sudden negative event.

Positives

• The appointment of Gilad Mamlok, a seasoned financial executive with three decades of experience in healthcare and technology, including capital markets, M&A, and investor relations, strengthens the company's financial leadership.
• The planned seamless transition, with Mr. Mamlok working alongside the outgoing CFO, Eyal Rubin, until October 2025, ensures continuity and minimizes disruption.
• Mr. Mamlok's prior experience with an initial public offering and other capital markets transactions at Sol-Gel Technologies Ltd. could be beneficial for Protalix's future strategic and financial initiatives.

Future Outlook

The company anticipates a seamless transition with the new Chief Financial Officer, Gilad Mamlok, who will work alongside the outgoing CFO, Eyal Rubin, until October 2025. The new CFO's annual bonus will be determined based on agreed-upon annual objectives, including measurable and strategic parameters, indicating a focus on future performance.

Management Comments

• "With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy, and I am delighted to welcome him to the Protalix team." Dror Bashan, President and Chief Executive Officer.
• "I also want to thank Mr. Rubin, both personally and on behalf of Protalix and its Board of Directors, for his unwavering dedication and leadership. Over the last six years, Eyal and I have worked in a close, collaborative manner in the management of the Company. He contributed significantly to Protalixs transformation, strengthening the Companys capital and financial status and preparing the Company for growth. We wish Eyal success in his future endeavors." Dror Bashan, President and Chief Executive Officer.

Industry Context

The appointment of a new Chief Financial Officer with extensive experience in capital markets, mergers and acquisitions, and business development within the healthcare and technology sectors suggests Protalix BioTherapeutics is positioning itself for potential strategic growth initiatives. This aligns with broader trends in the biopharmaceutical industry where companies often seek financial leadership capable of navigating complex capital raises, partnerships, and M&A activities to fund R&D and commercialization efforts for novel therapies like those in Protalix's pipeline (e.g., Elfabrio, PRX115, PRX119).

Comparison to Industry Standards

• The compensation package for the new CFO, including a base salary, performance-based bonus, stock options, and a change of control bonus, is consistent with standard executive compensation structures in the biopharmaceutical industry, particularly for publicly traded companies.
• The option grant of 0.75% of outstanding shares and an exercise price tied to the market price on the day preceding the grant are typical for executive inducement grants.
• The non-competition and non-solicitation clauses for one year post-employment are also standard practice to protect proprietary information and talent in competitive sectors like biotech.
• Specific comparable companies or projects are not mentioned in the document to allow for a direct quantitative comparison of results.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO could instill confidence in financial management and strategic direction, potentially impacting share price positively. The stock option grant aligns the new CFO's interests with shareholder value.
• Employees: The transition plan for the CFO role suggests stability in leadership.
• Customers/Suppliers/Creditors: No direct impact mentioned, but stable financial leadership generally benefits all external stakeholders.

Next Steps

• Gilad Mamlok to officially assume the role of Senior Vice President and Chief Financial Officer on August 24, 2025.
• Gilad Mamlok will continue working alongside Eyal Rubin to ensure a seamless transition until October 2025.
• The Board of Directors or Compensation Committee will determine Mr. Mamlok's annual discretionary bonus based on agreed-upon annual objectives.
• The Company and Mr. Mamlok will enter into an indemnification and release agreement prior to the Commencement Date of his employment.

Key Dates

Recommendation

Keywords

Protalix BioTherapeutics, PLX, CFO Appointment, Chief Financial Officer, Executive Change, Gilad Mamlok, Eyal Rubin, Biopharmaceutical, Healthcare, Financial Reporting, Corporate Governance, SEC Filing, 8-K, Capital Markets, Mergers and Acquisitions, Investor Relations